Combined Use of a Novel Cardioplegic Formula With MPS® Versus Cardioplexol ® in Urgent Isolated CABG Using MiECC in Patients With Recent Acute Myocardial Infarction
NCT ID: NCT04309994
Last Updated: 2020-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
307 participants
OBSERVATIONAL
2010-02-01
2020-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Use of a Novel Cardioplegic Formula With Myocardial Protection System (MPS)® Versus Cardioplexol ® in Isolated Coronary Artery Bypass Grafting (CABG) Using MiECC;
NCT03612388
Combined Use of a Novel Cardioplegic Formula With MPS ® Using the MiECC in Isolated CABG Versus OPCABG
NCT03609723
Effects of Microplegia on Transfusion Rates After Cardiac Surgery
NCT05076604
Histidine-Tryptophan-Ketoglutarate Solution Versus Blood Cardioplegia in CABG
NCT04203680
Study of Myocardial Contractility After Cardiac Surgery Under an Anterograde or Retrograde Cardioplegia
NCT02816385
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental
bypass surgery with blood cardioplegia by means of MPS
Myocardial protection system (MPS)
cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used
Active Comparator
bypass surgery with blood cardioplegia by means of Cardioplexol ®
Cardioplexol
cardioplegia solution
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Myocardial protection system (MPS)
cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used
Cardioplexol
cardioplegia solution
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Heart attack less than 7 days before surgery
Exclusion Criteria
* other inventions than CABG
* explicit will of the patient that his data may not be used
* denied general consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oliver Reuthebuch, Prof. Dr. med.
Role: PRINCIPAL_INVESTIGATOR
Cardiac Surgery Clinic, University Hospital Basel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiac Surgery Clinic University Hospital Basel
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-02383; ch20Reuthebuch
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.